Axalbion is a clinical-stage pharmaceutical company developing TRPM8 agonists for the treatment of chronic cough. Axalbion’s s strategy is to develop its lead compound AX-8 up-to Phase 2b to show clinical proof of concept across a representative patient population.


EPFL Innovation Park, 1015 Lausanne

Facts & figures
  • Type of organization
    Private company
  • Year of foundation
  • Number of employees in Switzerland
Key business